Sitting on a Pile of Cash 2.0? A Pharma with Strong Risk Benefits

$MEIP

MEI Pharma Inc. (NASDAQ:MEIP): this is an exponential Northside call, the sector analysts sees it having a best-in-class PI3Kδ inhibitor, which has demonstrated strong risk-benefit profile in Phase 1 lymphoma trials.

MEIP broke out on 6 April and has confirmed it Bull move, the Support is Strong at 2.53 and the Resistance is NIL, calling this stock at mininum 15/share long term, all Key indicators are Very Bullish in here.

Profile

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.

The company’s clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome.

Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML.

Plus, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer.

MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat, and a license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor, as well as related compounds.

Also, the company has a license agreement with CyDex Pharmaceuticals, Inc. for Captisol to use with ME-344, which are isoflavone-based drug compounds, a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene’s zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies, and a license agreement with Kyowa Kirin Co., Ltd. for ME-401.

The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in Y 2000 and is HQ’d in San Diego, California.

News

MEI Pharma, Inc. last week announced that Daniel P. Gold, PhD., President/CEO of MEI, will present a company overview and business update at the Jefferies Virtual Healthcare Conference on Tuesday, 2 June 2020 at 11:00a EDT.  The conference is being held in a virtual format. 

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at http://www.meipharma.com

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.

Have a healthy week, Keep the Faith!

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he it the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.